Appili Therapeutics Inc.
APLI.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.26% | 40.93% | 31.74% | 26.85% | 54.41% |
| Total Depreciation and Amortization | 5.21% | -2.97% | -4.90% | 12.36% | 28.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.67% | 50.85% | 458.67% | 68.62% | 8.46% |
| Change in Net Operating Assets | -76.34% | -52.68% | -129.24% | -15.71% | -0.42% |
| Cash from Operations | -397.83% | 264.33% | 133.12% | 80.52% | 101.58% |
| Capital Expenditure | 58.33% | -- | 92.31% | 93.03% | 95.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 119.23% | 119.23% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 28.57% | -440.00% | 92.13% | 95.56% | 97.41% |
| Total Debt Issued | -100.00% | -100.00% | 33.33% | -85.71% | -85.71% |
| Total Debt Repaid | -7.41% | -10.69% | -47.20% | -30.94% | -41.15% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13.54% | 27.71% | 20.96% | 80.27% | 79.14% |
| Cash from Financing | -210.00% | -151.66% | 57.42% | -91.38% | -91.66% |
| Foreign Exchange rate Adjustments | 7,087.50% | 5,950.00% | -- | 316.67% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -231.75% | 445.18% | 145.40% | 51.47% | 112.80% |